Hisashi Harada

Summary

Affiliation: Virginia Commonwealth University
Country: USA

Publications

  1. pmc Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity
    Hisashi Harada
    Department of Internal Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
    Proc Natl Acad Sci U S A 101:15313-7. 2004
  2. pmc MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM
    A A Rambal
    Department of Internal Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
    Leukemia 23:1744-54. 2009
  3. pmc GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy
    N Heidari
    Department of Internal Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
    Cell Death Dis 1:e76. 2010
  4. pmc Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells
    N Heidari
    Department of Internal Medicine, School of Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA
    Cell Death Dis 3:e349. 2012
  5. pmc Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer
    W Nakajima
    Department of Oral and Craniofacial Molecular Biology, School of Dentistry, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA
    Cell Death Dis 5:e1052. 2014
  6. pmc MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism
    Xin Yan Pei
    Departments of Medicine, Virginia Commonwealth University Massey Cancer Center, Richmond, VA 23298, USA
    Blood 110:2092-101. 2007
  7. pmc The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways
    Mohamed Rahmani
    Department of Medicine, Virginia Commonwealth University and Massey Cancer Center, Richmond, VA 23298, USA
    Blood 114:4507-16. 2009
  8. pmc Targeting the regulatory machinery of BIM for cancer therapy
    Hisashi Harada
    Department of Oral and Craniofacial Molecular Biology, Massey Cancer Center, Virginia Commonwealth University Health Sciences System, Richmond VA, 23298, USA
    Crit Rev Eukaryot Gene Expr 22:117-29. 2012
  9. ncbi request reprint 17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines
    Clint Mitchell
    Department of Biochemistry, Massey Cancer Center, Box 980035, Virginia Commonwealth University, Richmond, VA 23298 0035, USA
    Mol Cancer Ther 6:618-32. 2007
  10. pmc Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells
    Randolph M Abutin
    Department of Pharmacology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298 0035, USA
    Exp Hematol 37:151-8. 2009

Collaborators

Detail Information

Publications18

  1. pmc Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity
    Hisashi Harada
    Department of Internal Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
    Proc Natl Acad Sci U S A 101:15313-7. 2004
    ..Thus, ERK/mitogen-activated protein kinase-dependent phosphorylation of BIM in response to survival factor regulates BIM/BAX interaction and the pro-death activity of BIM...
  2. pmc MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM
    A A Rambal
    Department of Internal Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
    Leukemia 23:1744-54. 2009
    ..This study provides a rational foundation for future attempts to improve the activity of GCs with clinically relevant pharmacologic MEK inhibitors in the treatment of ALL and possibly other hematologic malignancies...
  3. pmc GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy
    N Heidari
    Department of Internal Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
    Cell Death Dis 1:e76. 2010
    ..Taken together, GX15-070 treatment in ALL could be an alternative regimen to overcome glucocorticoid resistance by inducing BAK-dependent apoptosis and ATG5-dependent autophagy...
  4. pmc Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells
    N Heidari
    Department of Internal Medicine, School of Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA
    Cell Death Dis 3:e349. 2012
    ..In conclusion, we identified the critical signaling pathway for GC-induced apoptosis, and targeting these molecules may be an alternative approach to overcome GC-resistance in leukemia treatment...
  5. pmc Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer
    W Nakajima
    Department of Oral and Craniofacial Molecular Biology, School of Dentistry, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA
    Cell Death Dis 5:e1052. 2014
    ..The precise regulatory mechanisms of Noxa/MCL-1 expression and stability could provide alternative targets to modulate apoptosis induced by BH3 mimetic drugs or other chemotherapeutic reagents. ..
  6. pmc MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism
    Xin Yan Pei
    Departments of Medicine, Virginia Commonwealth University Massey Cancer Center, Richmond, VA 23298, USA
    Blood 110:2092-101. 2007
    ....
  7. pmc The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways
    Mohamed Rahmani
    Department of Medicine, Virginia Commonwealth University and Massey Cancer Center, Richmond, VA 23298, USA
    Blood 114:4507-16. 2009
    ..Collectively, these findings suggest that Bim, and Mcl-1, but not Bad, integrate death signaling triggered by concomitant disruption of the PI3K/Akt and MEK1/2/ERK1/2 pathways in human leukemia cells...
  8. pmc Targeting the regulatory machinery of BIM for cancer therapy
    Hisashi Harada
    Department of Oral and Craniofacial Molecular Biology, Massey Cancer Center, Virginia Commonwealth University Health Sciences System, Richmond VA, 23298, USA
    Crit Rev Eukaryot Gene Expr 22:117-29. 2012
    ..It is likely that evolving insights into the factors that regulate BIM expression will ultimately lead to novel BIM-based therapeutic strategies in the future...
  9. ncbi request reprint 17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines
    Clint Mitchell
    Department of Biochemistry, Massey Cancer Center, Box 980035, Virginia Commonwealth University, Richmond, VA 23298 0035, USA
    Mol Cancer Ther 6:618-32. 2007
    ....
  10. pmc Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells
    Randolph M Abutin
    Department of Pharmacology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298 0035, USA
    Exp Hematol 37:151-8. 2009
    ..We investigated here the role of BIM in erythropoietin (EPO)-mediated survival in erythroid cells...
  11. ncbi request reprint p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells
    Jianghua Lu
    Department of Internal Medicine, Massey Cancer Center, Virginia Commonwealth University, Medical Sciences Building 215, Richmond, 23298, USA
    FEBS Lett 580:3539-44. 2006
    ..These findings indicate that BIM induction through p38-MAPK activation is a critical pathway in GC-induced cell death...
  12. pmc Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer
    Wataru Nakajima
    a Department of Oral and Craniofacial Molecular Biology, School of Dentistry, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
    Cancer Biol Ther 17:27-35. 2016
    ..These results suggest that combination of HDAC inhibitors and BCL-2 inhibitors could be an alternative and effective regimen for SCLC treatment. ..
  13. pmc Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor
    Anna V Miller
    Department of Oral and Craniofacial Molecular Biology, School of Dentistry, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
    PLoS ONE 8:e60685. 2013
    ..Our data suggest that BAK is the mediator of paclitaxel-induced apoptosis and could be an alternative target for overcoming paclitaxel resistance...
  14. ncbi request reprint Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation
    Shuang Chen
    Department of Medicine, Virginia Commonwealth University and Massey Cancer Center, Richmond, Virginia 23298, USA
    Cancer Res 67:782-91. 2007
    ..These findings provide a mechanistic basis for simultaneously targeting Mcl-1 and Bcl-2/Bcl-xL in leukemia...
  15. pmc Yet another function of p53--the switch that determines whether radiation-induced autophagy will be cytoprotective or nonprotective: implications for autophagy inhibition as a therapeutic strategy
    Shweta Chakradeo
    Departments of Medicine and Pharmacology and Toxicology, Massey Cancer Center S C, K S, A A, D B, N L, D A G, and Department of Oral and Craniofacial Molecular Biology, School of Dentistry H H, w n, W A Y, Virginia Commonwealth University, Richmond, Virginia and Departments of Molecular Biology and Biophysics S V T and Medicine F M T, University of Connecticut Health Sciences, Farmington, Connecticut
    Mol Pharmacol 87:803-14. 2015
    ..These observations are likely to have direct implications with respect to clinical efforts to modulate the response of malignancies to radiation through autophagy inhibition. ..
  16. pmc MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825
    Tri K Nguyen
    Department of Medicine, Massey Cancer Center, Virginia Commonwealth University, 401 College Street, Richmond, VA 23298, USA
    Blood 109:4006-15. 2007
    ..Together, these findings suggest that strategies combining dasatanib with MEK1/2 inhibitors warrant further investigation in Bcr/Abl(+) malignancies, particularly in the setting of imatinib mesylate-resistant disease...
  17. ncbi request reprint OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells
    Adly Yacoub
    Department of Biochemistry, Massey Cancer Center Virginia Commonwealth University, Richmond, VA 23298 0058, USA
    Mol Pharmacol 70:589-603. 2006
    ....
  18. ncbi request reprint Apoptosis regulators
    Hisashi Harada
    Department of Medicine, Virginia Commonwealth University, Medical College of Virginia, MCV Station, Box 230, Richmond, VA 23298, USA
    Rev Clin Exp Hematol 7:117-38. 2003
    ..It is likely that an improved understanding of apoptosis regulation will lead to new insights into neoplastic transformation, and may also provide important leads for the development of novel antileukemic strategies...